EXACT SCIENCES CORP Forms 3, 4 and 5: Restricted Stock Units and Performance Rights
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 20 rows in 2026. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2026-03-23: Reporting owner Baranick Brian; Form 4; Security Restricted Stock Units; Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2026-03-23: Reporting owner Herriott James; Form 4; Security Restricted Stock Units; Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2026-03-23: Reporting owner Bloomer Aaron; Form 4; Security Restricted Stock Units; Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2026-03-23: Reporting owner Bloomer Aaron; Form 4; Security Restricted Stock Units; Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-03-23 | Baranick Brian Officer (EVP, GM, Precision Oncology) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −28,063 0 owned after | no price filed | 2026-03-23 | |
| 2026-03-23 | Herriott James Officer (SVP, General Counsel & Sec) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −20,321 0 owned after | no price filed | 2026-03-23 | |
| 2026-03-23 | Bloomer Aaron Officer (EVP, Chief Financial Officer) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −4,395 0 owned after | no price filed | 2026-03-23 | |
| 2026-03-23 | Bloomer Aaron Officer (EVP, Chief Financial Officer) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −28,063 0 owned after | no price filed | 2026-03-23 | |
| 2026-03-23 | Condella Sarah Officer (EVP, Human Resources) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −23,224 0 owned after | no price filed | 2026-03-23 | |
| 2026-03-23 | Conroy Kevin T Director, Officer (President and CEO) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −18,143 0 owned after | no price filed | 2026-03-23 | |
| 2026-03-23 | Conroy Kevin T Director, Officer (President and CEO) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −44,336 0 owned after | no price filed | 2026-03-23 | |
| 2026-03-23 | Conroy Kevin T Director, Officer (President and CEO) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −83,360 0 owned after | no price filed | 2026-03-23 | |
| 2026-03-23 | Conroy Kevin T Director, Officer (President and CEO) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −154,829 0 owned after | no price filed | 2026-03-23 | |
| 2026-03-23 | ORVILLE JACOB A Officer (EVP, GM, Screening) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −38,707 0 owned after | no price filed | 2026-03-23 | |
| 2026-03-23 | Barber Michael J Director | 4 | Deferred Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,422 0 owned after | $0.00 | 2026-03-23 | |
| 2026-02-27 | Conroy Kevin T Director, Officer (President and CEO) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −18,143 18,143 owned after | $0.00 | 2026-03-03 | |
| 2026-02-27 | Conroy Kevin T Director, Officer (President and CEO) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −22,168 44,336 owned after | $0.00 | 2026-03-03 | |
| 2026-02-27 | Conroy Kevin T Director, Officer (President and CEO) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −27,786 83,360 owned after | $0.00 | 2026-03-03 | |
| 2026-02-25 | Condella Sarah Officer (EVP, Human Resources) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +23,224 23,224 owned after | $0.00 | 2026-02-27 | |
| 2026-02-25 | Herriott James Officer (SVP, General Counsel & Sec) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,321 20,321 owned after | $0.00 | 2026-02-27 | |
| 2026-02-25 | Conroy Kevin T Director, Officer (President and CEO) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +154,829 154,829 owned after | $0.00 | 2026-02-27 | |
| 2026-02-25 | Baranick Brian Officer (EVP, GM, Precision Oncology) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +28,063 28,063 owned after | $0.00 | 2026-02-27 | |
| 2026-02-25 | ORVILLE JACOB A Officer (EVP, GM, Screening) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +38,707 38,707 owned after | $0.00 | 2026-02-27 | |
| 2026-02-25 | Bloomer Aaron Officer (EVP, Chief Financial Officer) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +28,063 28,063 owned after | $0.00 | 2026-02-27 |